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Abstract
Objective
There are few published studies describing severe acute respiratory illness (SARI) epidemi-
ology amongst older children and adults from high HIV-prevalence settings. We aimed to
describe SARI epidemiology amongst individuals aged5 years in South Africa.
Methods
We conducted prospective surveillance for individuals with SARI from 2009–2012. Using
polymerase chain reaction, respiratory samples were tested for ten viruses, and blood for
pneumococcal DNA. Cumulative annual SARI incidence was estimated at one site with
population denominators.
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Findings
We enrolled 7193 individuals, 9% (621/7067) tested positive for influenza and 9% (600/6519)
for pneumococcus. HIV-prevalence was 74% (4663/6334). Among HIV-infected individuals
with available data, 41% of 2629 were receiving antiretroviral therapy (ART). The annual
SARI hospitalisation incidence ranged from 325-617/100,000 population. HIV-infected indi-
viduals experienced a 13–19 times greater SARI incidence than HIV-uninfected individuals
(p<0.001). On multivariable analysis, compared to HIV-uninfected individuals, HIV-infected
individuals were more likely to be receiving tuberculosis treatment (odds ratio (OR):1.7;
95%CI:1.1–2.7), have pneumococcal infection (OR 2.4; 95%CI:1.7–3.3) be hospitalised
for>7 days rather than<2 days (OR1.7; 95%CI:1.2–2.2) and had a higher case-fatality
ratio (8% vs 5%;OR1.7; 95%CI:1.2–2.3), but were less likely to be infected with influenza
(OR 0.6; 95%CI:0.5–0.8). On multivariable analysis, independent risk indicators associated
with death included HIV infection (OR 1.8;95%CI:1.3–2.4), increasing age-group, receiving
mechanical ventilation (OR 6.5; 95%CI:1.3–32.0) and supplemental-oxygen therapy
(OR 2.6; 95%CI:2.1–3.2).
Conclusion
The burden of hospitalized SARI amongst individuals aged5 years is high in South Africa.
HIV-infected individuals are the most important risk group for SARI hospitalization and mor-
tality in this setting.
Introduction
Pneumonia was the second leading underlying natural cause of death amongst persons
aged15 years in South Africa from 2009–2010 and pneumonia is an important cause of
morbidity and mortality in HIV-infected adults.[1, 2] There are few published studies estimat-
ing the incidence and viral aetiology of severe acute respiratory illness (SARI) amongst older
children and adults from high HIV-prevalence settings in Sub-Saharan Africa.[3]
Data on the burden, severity and aetiology of SARI amongst HIV-infected and -uninfected
older children and adults are necessary to guide the relative prioritisation of prevention and
control efforts. In South Africa, the HIV prevalence amongst individuals aged 15–49 years, the
age group with the highest prevalence of HIV, was estimated to be 17% in 2012.[4] South Af-
rica embarked on a national programme of provision of antiretroviral therapy (ART) in 2004.
[5] ART coverage amongst eligible HIV-infected adults (CD4+ T cell count<350/mm3) in
South Africa was estimated to be 29% in 2009 and 52% in 2011.[6]
We aimed to describe the incidence, viral aetiology and factors associated with death
amongst HIV-infected and -uninfected individuals aged5 years hospitalised with SARI in
South Africa from 2009 through 2012.
Methods
Description of the surveillance programme
From February 2009, active, prospective, hospital-based surveillance (the Severe Acute Respira-
tory Illness (SARI) programme) was implemented in three of the nine provinces of South
Africa (Chris Hani-Baragwanath Academic Hospital (CHBAH) in an urban area of Gauteng
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Province, Edendale Hospital in a peri-urban area of KwaZulu-Natal Province and Matikwana
and Mapulaneng Hospitals in a rural area of Mpumalanga Province). In June 2010, an addi-
tional surveillance site was introduced at Klerksdorp and Tshepong Hospitals in a peri-urban
area of the Northwest Province.
Case definition
A case of SARI was defined as a hospitalised individual with symptom onset less than seven
days prior to admission meeting an adapted World Health Organisation (WHO) case defini-
tion for SARI: (1) sudden onset of fever (>38°C) or reported fever, (2) cough or sore throat,
and (3) shortness of breath, or difficulty breathing.[7]
Study procedures
All patients admitted during Monday through Friday were eligible, except for adult patients at
CHBAH where enrolment occurred for two of every five working days (enrolment days varied
systematically according to the intake days of the two participating wards) per week due to
large patient numbers and limited resources. Daily numbers of patients admitted, numbers
screened, numbers meeting study case definitions and numbers enrolled were collected in
study logs. Study staff completed case report forms until discharge and collected nasopharyn-
geal (NP) and throat swabs as well as blood specimens for pneumococcal testing from consent-
ing patients. Hospital and ICU admission and collection of specimens for CD4+ T-cell counts
was performed at the discretion of the attending-physician. Underlying medical conditions
were defined as documented presence of asthma, other chronic lung disease, chronic heart dis-
ease, liver disease, renal disease, diabetes mellitus, immunocompromising conditions (exclud-
ing HIV infection) or neurological disease.
Laboratory methods
NP and throat swabs were transported in a single viral transport medium tube at 4–8°C to the
National Institute for Communicable Diseases (NICD) within 72 hours of collection. Respira-
tory specimens were tested by a multiplex real-time reverse-transcription polymerase chain re-
action (PCR) assay for influenza A and B viruses, parainfluenza virus 1–3, respiratory syncytial
virus (RSV), enterovirus, human metapneumovirus (hMPV), adenovirus and human rhinovi-
rus.[8] Influenza positive specimens were subtyped using the US Centers for Disease Control
and Prevention (CDC) real-time reverse-transcription PCR protocol for characterisation of in-
fluenza virus. Streptococcus pneumoniae was identified by quantitative real-time PCR detecting
the lytA gene from whole blood specimens.[9] The focus of the surveillance programme was
viral pathogens and pneumococcus, therefore patients were not systematically tested for tuber-
culosis or other respiratory pathogens.
Evaluation of HIV sero-status
HIV-infection status data was obtained based on testing undertaken as part of standard-of-
care,[10] or through anonymised linked dried blood spot specimen testing by enzyme-linked
immunosorbent assay (ELISA) in patients providing written informed consent. Results from
anonymised testing were used preferentially if both standard-of-care and anonymised results
were available. CD4+ T-cell counts were determined by flow cytometry.[11] Patients were cate-
gorised into two immunosuppression categories: (1) moderate immunosupression (CD4+ T-
lymphocytes200/mm3), or (2) severe immunosuppression (CD4+ T-lymphocytes<200/mm3).
SARI Epidemiology South Africa
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[12] Patients diagnosed by clinicians as HIV-infected on the current admission were referred
for HIV management as part of routine care.
Calculation of incidence
Calculation of incidence was conducted at one surveillance site (CHBAH) where population
denominator data were available. This hospital is the only public hospital serving a community
of about 1.8 million persons aged5 years in 2012 amongst whom ~10% have private medical
insurance.[13] The vast majority (>80%) of uninsured individuals and approximately 10% of
medically-insured individuals seek care at public hospitals, consequently the majority of indi-
viduals requiring hospitalisation from this community are admitted to CHBAH. We estimated
the total number of SARI hospitalisations from the number of enrolled individuals adjusting
for non-enrollment in three of five adult wards and during weekends and refusal to participate
using information from study logs. The total number of SARI hospitalizations at CHBAH was
obtained using the following formula:
SARITotal ij ¼ SARIEnrolled ij  ð5=2Þ  ð7=5Þ  ð1=X ijÞ ð1Þ
Where SARITotalij is the estimated total number of SARI hospitalization in year i (2009–
2012) and age group j (5–14, 15–24, 25–44, 45–64 and65 years of age); SARIEnrolledij is the
number of SARI cases enrolled in year i and age group j; 5/2 is the coefficient used to adjust for
enrolment of patients in 2/5 adult wards; 7/5 is the coefficient used to adjust for non-enrolment
over weekends; and Xij is the proportion of all eligible cases that were enrolled in year i and age
group j. The adjustment factor varied from 2.2 to 7.9 depending on the age-group and year of
enrolment. We estimated incidence of SARI hospitalisations per 100,000 individuals by age
groups and HIV status using the adjusted number of SARI hospitalisations divided by the mid-
year total population estimates for each year, multiplied by 100,000.[14] HIV prevalence in the
study population was estimated from the projections of the Actuarial Society of South Africa
AIDS and Demographic model.[4] For estimation of incidence, we assumed that the HIV prev-
alence by age group amongst patients not tested for HIV was the same as that amongst
those tested.
Confidence intervals for incidence estimates were calculated using the Poisson distribution.
Age-specific and overall age-adjusted relative risk of SARI hospitalisation in HIV-infected
compared to -uninfected persons was determined using log-binomial regression. To explore
the possible effect of missing data on estimates of hospitalisation incidence by HIV status, we
conducted a sensitivity analysis in which all cases not tested for HIV were assumed to be
HIV uninfected.
Analysis of factors associated with HIV sero-status and death
Univariable and multivariable analyses were performed with Stata version 12 (StataCorp Limit-
ed, College Station, United States). To identify factors associated with HIV-infection status and
death among SARI patients we implemented multivariable logistic regression models, starting
with all variables that were significant at p<0.1 on univariable analysis and dropping non-sig-
nificant factors with stepwise backward selection. All pairwise interactions of factors significant
at the final multivariable additive model were evaluated. Two-sided p-values<0.05 were con-
sidered significant. For each univariable analysis, we used all available case information. In the
multivariable model, patients with missing data for included variables were dropped from the
model. Age group, duration of hospitalisation and year of admission were defined as categori-
cal variables in multiple levels. All other variables were defined as the presence or absence of
SARI Epidemiology South Africa
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the attribute excluding missing data. To explore possible bias, individuals tested for HIV were
compared to those not tested.
Ethical considerations
The protocol was approved by the Research Ethics Committees of the Universities of the Wit-
watersrand and KwaZulu-Natal. This surveillance was deemed non-research by the U.S. CDC
and did not need human subjects review by that institution. Written informed consent was ob-
tained from all participants.
Results
Demographic, clinical characteristics and aetiology
From February 2009 through December 2012, 7977 individuals5 years of age who fulfilled
the SARI case definition were screened for study enrolment, of whom 7193 (90%) were en-
rolled (Fig. 1). The most common reasons for non-enrolment were being confused or too ill to
consent (55%) and study refusal (11%). Of the 7193 enrollees, 8% were 5–14 years of age, 8%
15–24 years, 53% 25–44 years, 25% 45–64 years and 6%65 years (Table 1). The majority of
subjects were enrolled at CHBAH (76%), and 61% were female. Among patients with available
information, the overall case-fatality ratio was 7%.
HIV-infection status was available for 6334 (88%) of enrolled individuals. Age-specific HIV
prevalence findings were not significantly different when only patients tested through anon-
ymised linked testing were included (data not shown). When comparing patients tested for
HIV to those not tested for HIV, controlling for year of test, surveillance site and age group
there were no differences in patient epidemiologic characteristics or case-fatality ratios (data
not shown). The overall HIV prevalence among persons5 years with available data was 74%
(4663/6334) and was highest in the 25–44 year age group (88%, 3016/3421) (Table 1). Twelve
percent of individuals had an underlying medical condition, excluding HIV. 53 women were
pregnant. Only 14 individuals reported having been vaccinated against influenza in the current
year and no subject had received pneumococcal vaccines.
Enrolment occurred throughout the year and peaked in the winter months (May-August)
(Fig. 2). Overall, among those tested for respiratory viruses, 18% were positive for rhinovirus,
10% for adenovirus and 9% for influenza (Table 2). Other respiratory viruses tested positive in
less than 5% of individuals. Adenovirus, rhinovirus and enterovirus were more commonly
identified in individuals 5–14 years old than other age groups. Also, 9% of subjects tested posi-
tive for pneumococcus on PCR of whole blood specimens. The detection of influenza virus-as-
sociated SARI peaked during the winter months (Fig. 2). Although pneumococcus (on lytA
PCR or culture) was detected perennially, detection increased during winter-months of at least
two years (2009 and 2010).
Incidence of hospitalisation in HIV-infected and -uninfected patients
The annual incidence of hospitalisation (per 100,000) for SARI at CHBAH ranged between 325
(95% CI 315–335) in 2012 and 617 (95% CI 603–632) in 2010 and was highest in the 45–64
year age-group; annual range 501 to 1284 (Table 3). HIV-infected individuals experienced an
age-adjusted increased relative risk of 13 to 19 times for SARI hospitalisation compared to
HIV-uninfected individuals. On sensitivity analysis, assuming that all patients not tested for
HIV were HIV-uninfected, the trend towards a higher incidence of SARI hospitalisations in
HIV-infected individuals remained in all age groups and years.
SARI Epidemiology South Africa
PLOS ONE | DOI:10.1371/journal.pone.0117716 February 23, 2015 5 / 16
Fig 1. Flow chart of patients aged5 years included in the study. SARI—severe acute respiratory illness, HIV—human immunodeficiency virus.
doi:10.1371/journal.pone.0117716.g001
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Table 1. Comparison of the clinical and epidemiologic characteristics of HIV-infected and -uninfected individuals aged 5 years hospitalised
with severe acute respiratory illness (SARI) at four sentinel surveillance sites, South Africa, 2009–2012.
Characteristics All patients
n/N (%)
HIV-infected
n/N (%)
HIV-uninfected
n/N (%)
Univariable
analysis†
Multivariable
analysis††
OR(95% CI) p OR (95% CI) p
Demographic characteristics
Age group (years) 5–
14
579/7193 (8) 191/4663 (4) 185/1671 (11) Reference <0.001 Reference <0.001
15–
24
599/7193 (8) 336/4663 (7) 192/1671 (11) 1.7 (1.3–2.2) 1.1 (0.8–1.6)
25–
44
3784/7193
(53)
3016/4663
(65)
405/1671 (24) 7.2 (5.7–9.1) 5.4 (4.1–7.2)
45–
64
1778/7193
(25)
1047/4663
(22)
564/1671 (34) 1.8 (0.4–2.3) 1.6 (1.2–2.1)
65 453/7193 (6) 73/4663 (2) 325/1671 (19) 0.2 (0.2–0.3) 0.2 (0.1–0.3)
Female 4413/7193
(61)
3037/4663
(65)
891/1671 (53) 1.6 (0.5–1.87) <0.001 1.7 (1.5–2.0) <0.001
Black African race 6998/7185
(97)
4597/4659
(99)
1573/1670 (94) 4.5 (3.3–6.3) <0.001 3.8 (2.6–5.6) <0.001
Underlying medical conditions
Underlying medical condition
excluding tuberculosis and HIV*
879/7191
(12)
345/4663 (7) 433/1671 (26) 0.2 (0.2–0.3) <0.001 0.3 (0.2–0.4) <0.001
Underlying tuberculosis (receiving
tuberculosis treatment on
admission)
276/7167 (4) 217/4646 (5) 28/1668 (2) 2.9 (1.9–4.3) <0.001 2.1 (1.3–3.2) 0.002
Alcohol use 1175/7174
(16)
729/4650
(16)
344/1667 (21) 0.7 (0.6–0.8) <0.001 0.6 (0.5–0.7) <0.001
Smoking 1029/7175
(14)
625/4651
(13)
310/1667 (19) 0.7 (0.6–0.8) <0.001
Infectious agents identified
Pneumococcus** 600/6519 (9) 499/4506
(11)
70/1601(5) 2.7 (2.1–3.5) <0.001 2.2 (1.6–2.9) <0.001
Influenza (any type) 621/7067 (9) 350/4609 (8) 185/1650 (11) 0.7 (0.5–0.8) <0.001 0.6 (0.5–0.8) <0.001
Influenza A 366/7067 (5) 190/4609 (4) 113/1650 (7) 0.6 (0.5–0.7) <0.001
Influenza B 246/7067 (3) 153/4609 (3) 70/1650 (4) 0.8 (0.6–1.0) 0.083
Parainfluenzavirus 2 43/7052 (1) 31/4610 (1) 3/1636 (<1) 3.7 (1.1–12.1) 0.031
Any virus identified*** 2279/7056
(32)
1507/4608
(33)
473/1640 (29) 1.2 (1.1–1.4) 0.004
Clinical presentation and course
Symptoms 2 days prior to
admission
5934/7059
(84)
3998/4576
(87)
1296/1636 (79) 1.8 (1.6–2.1) <0.001 1.6 (1.3–1.9) <0.001
Admission to intensive care 11/7165
(<1)
7/4650 (<1) 2/1665 (<1) 1.3 (0.3–6.0) 0.778
Mechanical ventilation 11/7167
(<1)
5/4651 (<1) 3/1666 (<1) 0.6 (0.1–2.5) 0.480
Oxygen required 2682/7164
(37)
1788/4649
(38)
641/1666 (38) 1.0 (0.9–1.1) 0.991
Antibiotics prescribed on admission 6787/7002
(97)
4468/4569
(98)
1549/1630 (95) 2.3 (1.7–3.1) <0.001 2.5 (1.7–3.6) <0.001
Duration of hospitalisation (days) <2 525/7092 (7) 208/4605 (5) 158/1647 (10) Reference <0.001 Reference
2–7 4014/7092
(57)
2580/4605
(56)
1016/1647 (62) 1.9 (1.5–2.4) 1.6 (1.2–2.1)
>7 2553/7092
(36)
1817/4605
(39)
473/1647 (29) 2.9 (2.3–3.7) 2.4 (1.8–3.2)
(Continued)
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Characteristics of HIV-infected patients and factors associated with HIV
infection
Compared to HIV-uninfected cases, using multivariable analysis, in addition to other factors,
HIV-infected subjects were more likely to be receiving tuberculosis treatment at admission
(OR 1.7; 95%CI: 1.1–2.7), have pneumococcal infection (OR 2.4; 95%CI: 1.7–3.3), be
Table 1. (Continued)
Characteristics All patients
n/N (%)
HIV-infected
n/N (%)
HIV-uninfected
n/N (%)
Univariable
analysis†
Multivariable
analysis††
OR(95% CI) p OR (95% CI) p
Case-fatality ratio 514/7154 (7) 352/4642 (8) 87/1660 (5) 1.5 (1.2–1.9) 0.001 1.6 (1.2–2.2) 0.002
OR—Odds ratio, CI—confidence interval, HIV—human immunodeficiency virus, CHBAH—Chris Hani Baragwanath Academic Hospital
† HIV-infected vs uninfected
†† HIV-infected vs uninfected. Odds ratios and p values shown for all variables included in the multivariable model
* Asthma, other chronic lung disease, chronic heart disease (valvular heart disease, coronary artery disease, or heart failure excluding hypertension), liver
disease (cirrhosis or liver failure), renal disease (nephrotic syndrome, chronic renal failure), diabetes mellitis, immunocompromising conditions excluding
HIV infection (organ transplant, immunosuppressive therapy, immunoglobulin deficiency, malignancy), neurological disease (cerebrovascular accident,
spinal cord injury, seizures, neuromuscular conditions) or pregnancy. Comorbidities were considered absent in cases for which the medical records stated
that the patient had no underlying medical condition or when there was no direct reference to that condition.
**Positive on lytA PCR
***Infection with at least one of influenza, parainfluenza virus 1, 2 and 3; respiratory syncytial virus; enterovirus; human metapneumovirus; adenovirus;
rhinovirus in addition to influenza
doi:10.1371/journal.pone.0117716.t001
Fig 2. Number of patients enrolled with SARI and influenza, pneumococcal and respiratory syncytial virus (RSV) detection rates by epidemiologic
week and year at four sentinel surveillance sites, South Africa, 2009–2011.
doi:10.1371/journal.pone.0117716.g002
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hospitalised for>7 days (OR 1.7; 95%CI: 1.2–2.3 as compared to<2 days), and had a higher
case-fatality ratio (OR1.7; 95%CI: 1.2–2.3; Table 1). In contrast, HIV-infected subjects were
less likely to have an underlying medical condition (OR 0.3; 95%CI: 0.2–0.3), or be infected
with influenza (OR 0.6; 95%CI: 0.5–0.8).
Only 1455 (31%) of 4663 HIV-infected patients had available CD4+ T cell count data, of
whom 68% (987) had CD4+ T-lymphocyte cell counts<200/mm3. The case-fatality ratio was
significantly higher in HIV-infected subjects with severe immunosuppression (12%, 117/983)
than those with CD4+ T-lymphocyte count of>200/mm3 (5%, 22/462, p<0.001). Of those
with available data, 41% (1083/2629) reported currently receiving ART and 34% (1566/4569)
reported receiving prophylaxis with trimethoprim-sulfamethoxazole. The case-fatality ratio
was similar in individuals receiving (7%, 80/1075) and not receiving ART (vs. 8%, 121/1536,
p = 0.681). The proportion of patients with CD4+ T-lymphocyte cell counts<200/mm3 was
higher in patients not receiving ART (388/571, 68%) as compared to patients receiving ART
(221/392, 56%).
Factors associated with mortality
The overall case fatality ratio was 7% (514/7154), with a median age of 42 years (interquartile
range 23–74) in those who died. The case-fatality ratio was 1.5 times greater amongst HIV-in-
fected (8%) as compared to HIV-uninfected (5%) individuals with SARI (Table 4). On multi-
variable analysis, independent risk indicators associated with death included increasing age
group, HIV infection (OR 1.8 95%CI: 1.3–2.4), receipt of mechanical ventilation (OR 6.5; 95%
CI: 1.3–32.0) and receiving supplementary-oxygen therapy (OR 2.6; 95%CI: 2.1–3.2) (Table 4).
Discussion
More than two thirds (>70%) of individuals aged5 years hospitalised with SARI in South Af-
rica are co-infected with HIV, making this by far the most important underlying risk condition
for this syndrome even in the era of widespread availability of ART. HIV-infected individuals
had a 13–19 times greater incidence of SARI hospitalisation than HIV-uninfected individuals
Table 2. Percentage of patients testing positive for viral and bacterial pathogens by age group amongst individuals aged 5 years hospitalised
with severe acute respiratory illness (SARI) at four sentinel surveillance sites, South Africa, 2009–2012.
Age group (years) 5–14 n/N (%) 15–24 n/N (%) 25–44 n/N (%) 45–64 n/N (%) 65 n/N (%) All ages p*
Influenza 64/560 (11) 64/590 (11) 306/3715 (8) 139/1756 (8) 48/446 (11) 621/7067 (9) 0.010
Adenovirus 115/489 (24) 49/520 (9) 286/3403 (8) 139/1628 (8) 25/413 (6) 613/6453 (10) <0.001
Enterovirus 43/550 (8) 12/585 (2) 40/3715 (1) 17/1756 (1) 7/446 (2) 119/6933 (2) <0.001
Rhinovirus 189/550 (34) 128/585 (22) 652/3715 (18) 249/1756 (14) 49/446 (11) 1267/7049 (18) <0.001
Human metapneumovirus 13/550 (2) 9/585 (2) 68/3715 (2) 26/1756 (1) 8/446 (2) 124/7052 (2) 0.694
Parainfluenzavirus 1 3/550 (1) 2/585 (<1) 11/3715 (<1) 9/1756 (1) 3/446 (1) 28/7052 (<1) 0.599
Parainfluenzavirus 2 8/550 (1) 4/585 (1) 25/3715 (1) 6/1756 (<1) 0/446 (0) 43/7052 (1) 0.021
Parainfluenzavirus 3 7/550 (1) 17/585 (3) 67/3715 (2) 27/1756 (2) 9/446 (2) 127/7050 (2) 0.220
Respiratory syncytial virus 36/550 (7) 21/585 (4) 171/3715 (5) 77/1756 (4) 16/446 (4) 321/7052 (5) 0.118
Any respiratory viral infection 315/550 (57) 209/585 (36) 1159/3715 (31) 491/1756 (28) 105/446 (24) 2279/7056 (32) <0.001
Infection with >1 respiratory virus 108/550 (19) 47/585 (8) 211/3715 (6) 85/1756 (5) 19/446 (4) 470/7056 (7) <0.001
Pneumococcus** 24/381 (6) 48/553 (9) 348/3507 (10) 166/1655 (10) 14/423 (3) 600/6519 (9) <0.001
*chi squared test
**On lytA PCR
doi:10.1371/journal.pone.0117716.t002
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Table 3. Incidence of severe acute respiratory illness (SARI) hospitalisations per 100,000 population by year and HIV status at Chris Hani-
Baragwanath Hospital, South Africa.
Year Age group
(years)
IR (95% CI) All
patients
IR (95% CI) HIV
infected
IR (95% CI) HIV
uninfected
RR (95% CI) HIV infected
vs HIV uninfected
RR (95% CI) HIV infected vs HIV
uninfected sensitivity analysis
R
2009 5–14 126 (112–141) 1833 (1496–
2227)
82 (71–96) 22.1 (17.2–28.4) 6.9 (4.8–9.6)
15–24 283 (261–308) 2005 (1806–
2223)
110 (95–126) 18.2 (15.3–21.8) 12.3 (10.4–14.5)
25–44 846 (818–875) 2947 (2845–
3053)
101 (90–114) 29.0 (25.8–32.8) 11.8 (10.8–12.8)
45–64 925 (882–970) 4682 (4403–
4973)
400 (370–432) 11.7 (10.6–12.9) 8.7 (7.9–9.5)
65 624 (562–690) 8777 (6488–
1152)
544 (487–608) 16.1 (11.7–21.7) 12.1 (8.5–16.9)
All (5
years)
591 (577–606) 3072 (2985–
3162)
179 (171–188) 18.1 (17.0–19.3)* 10 (9.8–11.0)*
2010 5–14 65 (56–76) 876 (670–1126) 42 (35–52) 20.5 (14.7–28.4) 8.4 (5.5–12.5)
15–24 206 (187–226) 1665 (149–
1858)
67 (56–79) 24.9 (20.3–30.6) 17.5 (14.5–21.3)
25–44 753 (727–779) 2576 (248–267) 105 (95–117) 24.3 (21.8–27.3) 13.5 (12.4–14.8)
45–64 1284 (1237–
1334)
7025 (671–735) 456 (426–488) 15.4 (14.2–16.7) 12.4 (11.4–13.4)
65 1101 (1022–
1185)
19793 (16749–
23169)
878 (808–954) 22.5 (18.7–26.9) 20.5 (16.9–24.6)
All (5
years)
617 (603–632) 3175 (3091–
3262)
194 (186–203) 19.3 (18.2–20.4)* 13.6 (12.9–14.3)*
2011 5–14 36 (29–44) 376 (252–541) 25 (20–33) 14.4 (9.0–22.7) 9.4 (5.5–15.5)
15–24 150 (134–167) 998 (859–115) 74 (63–87) 13.4 (10.8–16.7) 12.6 (10.1–15.6)
25–44 588 (566–611) 1914 (1837–
1996)
117 (106–130) 16.3 (14.7–18.3) 14.4 (13.0–16.0)
45–64 641 (608–677) 3056 (2854–
3269)
282 (259–308) 10.8 (9.7–12.1) 10 (9.0–11.2)
65 419 (372–470) 2490 (1564–
3633)
389 (344–440) 6.3 (3.9–9.5) 6 (3.7–9.2)
All (5
years)
389 (378–401) 1934 (1869–
2001)
134 (127–141) 13.1 (12.2–14.0)* 11.9 (11.1–12.7)*
2012 5–14 33 (26–41) 285 (186–431) 25 (19–32) 11.6 (6.9–18.8) 5.9 (3.1–10.6)
15–24 134 (119–149) 1154 (1002–
1323)
48 (40–59) 23.8 (18.7–30.5) 14.6 (11.6–18.4)
25–44 505 (485–527) 1665 (1592–
1741)
94 (84–106) 17.6 (15.6–19.9) 8.9 (8.1–9.8)
45–64 501 (472–532) 2448 (2271–
2635)
203 (184–225) 12 (10.6–13.6) 9 (8.0–10.2)
65 337 (296–381) 5260 (4052–
6692)
252 (217–291) 20.8 (15.4–27.8) 16.6 (12.1–22.5)
All (5
years)
325 (315–335) 1703 (1642–
1766)
99 (93–105) 15.8 (14.7–17.1)* 9.6 (8.9–10.3)*
IR—incidence rate, RR—relative risk, CI—confidence interval, HIV—human immunodeficiency virus
Significant relative risk value at p<0.05 are in bold
R
Assuming that all patients not tested for HIV are HIV negative
*Age-adjusted
doi:10.1371/journal.pone.0117716.t003
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Table 4. Factors associated with death amongst patients aged 5 years hospitalised with severe acute respiratory illness (SARI) at four sentinel
surveillance sites, South Africa, 2009–2012†.
Characteristics Case-fatality ratio
(%)
Univariable
analysis
Multivariable
analysis†
OR (95% CI) p OR (95% CI) p
Demographic characteristics
Age group (years) 5–14 12/577 (2) Reference <0.001 Reference <0.001
15–24 28/594 (5) 2.3 (1.2–4.6) 3.0 (1.2–7.5)
25–44 255/3760 (7) 3.4 (1.9–6.2) 3.4 (1.5–7.9)
45–64 171/1774 (10) 5.0 (2.8–9.1) 5.9 (2.5–13.7)
65 48/449 (11) 5.6 (3.0–10.7) 9.1 (3.7–22.2)
Race Other race 6/187 (3) Reference 0.038 Reference 0.033
Black African 508/6959 (7) 2.4 (1.0–5.4) 3.5 (1.1–11.2)
Site CHBAH 371/5424 (7) Reference 0.016 Reference 0.001
Matikwana/
Mapulaneng
77/948 (8) 1.2 (0.9–1.6) 1.8 (1.3–2.6)
Edendale 55/554 (10) 1.5 (1.1–2.0) 1.6 (1.1–2.4)
Klerksdorp 11/228 (5) 0.7 (0.4–1.3) 0.9 (0.5–1.8)
Underlying medical conditions
HIV status Negative 87/1660 (5) Reference 0.001 Reference <0.001
Positive 352/4642 (8) 1.5 (1.2–1.9) 1.8 (1.3–2.4)
Underlying medical condition* No 456/6281 (7) Reference 0.52
Yes 58/871 (6) 0.9 (0.7–1.2)
Underlying tuberculosis No 475/6854 (7) Reference <0.001 Reference 0.001
Yes 36/274 (13) 2.0 (1.4–2.9) 2.0 (1.3–3.0)
Infectious agents identified
Pneumococcus** No 413/5885(7) Reference 0.187
Yes 50/597 (8) 1.2 (0.9–1.6)
Influenza No 473/6413 (7) Reference 0.014
Yes 29/616 (5) 0.6 (0.4–0.9)
Clinical presentation and course
Duration of symptoms prior to
admission
< 2 days 56/1122 (5) Reference 0.003 Reference 0.039
 2 days 441/5899 (7) 1.5 (1.2–2.0) 1.4 (1.0–2.0)
ICU admission No 511/7133 (7) Reference 0.01
Yes 3/11 (27) 4.9 (1.3–18.4)
Mechanical ventilation No 510/7135 (7) Reference <0.001 Reference 0.022
Yes 4/11 (36) 7.4 (2.2–25.4) 6.5 (1.3–32.0)
Oxygen therapy No 215/4466 (5) Reference <0.001 Reference <0.001
Yes 299/2677 (11) 2.5 (2.1–3.0) 2.6 (2.1–3.2)
Antibiotics prescribed on admission No 19/215 (9) Reference 0.349
Yes 484/6760 (7) 0.8 (0.5–1.3)
Duration of hospitalisation (days) <2 39/523 (7) Reference 0.002 Reference <0.001
2–7 252/4011 (6) 0.8 (0.6–1.2) 0.5 (0.3–0.7)
(Continued)
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and also experienced prolonged hospitalisation and increased risk of death. The spectrum of
viral infectious agents identified from HIV-infected and -uninfected individuals was generally
similar, however HIV-infected individuals were more likely to test positive for pneumococcus.
The overall incidence of SARI hospitalisation ranged from 325–617/100,000, somewhat
greater than was described in another high HIV-prevalence setting in Kenya (229/100,000).
[15] The incidence of SARI hospitalisation in HIV-uninfected individuals aged5 years ran-
ged from 99–194/100,000 population each year, similar to what has been described from low
HIV-prevalence middle income countries such as Bangladesh (110–130/100,000) and Thailand
(incidence in all ages 177–580/100,000) and slightly lower than the incidence in US adults
(267/100,000).[16–18] Differences in incidence observed in different settings may be related to
differences in health-seeking behavior, differing thresholds for hospital admission and case def-
initions or may reflect real differences. The 13–19 times elevated incidence (1703–3175/
100,000) of hospitalised SARI which we observed in HIV-infected individuals was somewhat
greater than the 4 times elevated incidence described in HIV-infected adults from Kenya with
outpatient and hospitalised ARI.[3] Amongst HIV-infected individuals the peak incidence was
in the 25–64 years age group, the age group most affected by HIV. Amongst HIV-uninfected
individuals, incidence increased with increasing age, similar to that seen in low HIV-prevalence
countries.[18]
We identified at least one respiratory virus in approximately one-third of all patients, simi-
lar to other studies from adults.[19, 20] The prevalence of detection of most respiratory viruses
was highest in the 5–14 year age-group and decreased with increasing age. Rhinovirus and ade-
novirus were most commonly detected, followed by influenza. While the detection of influenza
virus in persons aged5 years with SARI likely reflects an aetiologic role, the clinical relevance
of many of the other respiratory viruses is unclear without a comparison to controls.[3, 19]
Pneumococcus was identified in 9% of individuals overall with the highest detection rate in
persons aged 25–64 years, the age group most affected by HIV. While real-time PCR is more
sensitive than blood culture for diagnosing pneumococcal SARI, additional cases of pneumo-
coccal co-infection may still have been missed.[21] Healthy adults are rarely colonized with the
pneumococcus and previous studies have found the lytA PCR on blood to be negative in
healthy children colonized with the pneumococcus [22–24]. For this reason, we feel that detec-
tion of this target in the blood of these SARI patients likely serves as a specific marker for pneu-
mococcal disease. Sterile specimen cultures for bacteria were performed uncommonly (<15%
Table 4. (Continued)
Characteristics Case-fatality ratio
(%)
Univariable
analysis
Multivariable
analysis†
OR (95% CI) p OR (95% CI) p
>7 219/2552 (9) 1.2 (0.8–1.7) 0.6 (0.4–1.0)
OR—Odds ratio, CI—confidence interval, HIV—human immunodeficiency virus, CHBAH—Chris Hani Baragwanath Academic Hospital
†Additional factors evaluated and found to be non-significant on univariable analysis: sex, alcohol, smoking, and infection with adenovirus, enterovirus,
rhinovirus, human metapneumovirus, parainfluenza virus 1, 2 and 3 and respiratory syncytial virus
*Asthma, other chronic lung disease, chronic heart disease (valvular heart disease, coronary artery disease, or heart failure excluding hypertension), liver
disease (cirrhosis or liver failure), renal disease (nephrotic syndrome, chronic renal failure), diabetes mellitis, immunocompromising conditions excluding
HIV infection (organ transplant, immunosuppressive therapy, immunoglobulin deficiency, malignancy), neurological disease (cerebrovascular accident,
spinal cord injury, seizures, neuromuscular conditions) or pregnancy. Comorbidities were considered absent in cases for which the medical records stated
that the patient had no underlying medical condition or when there was no direct reference to that condition.
**On lytA PCR
doi:10.1371/journal.pone.0117716.t004
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of patients) and thus we were not able to compare bacterial culture with PCR results. On multi-
variable analysis pneumococcus was significantly more likely to be detected in HIV-infected
than HIV-uninfected individuals, likely reflecting the very high relative risk of hospitalisation
for pneumococcal SARI in HIV-infected adults.[25] Pneumococcal polysaccharide vaccine is
used uncommonly in South Africa, but this vaccine is not recommended for HIV-infected
adults.[26] Although more recent data suggest that the pneumococcal conjugate vaccine may
be effective in HIV-infected adults in Africa, [27] there is no specific recommendation for this
vaccine in adults in South Africa. The pneumococcal conjugate vaccine was introduced into
the routine childhood immunisation programme in 2009. This may have impacted on the pro-
portion of patients testing positive for pneumococcus over time as a result of indirect protec-
tion conferred to unvaccinated adults.[28, 29]
In contrast to pneumococcus, influenza virus was significantly less commonly identified
from HIV-infected individuals. We have previously demonstrated, in the same population,
that HIV-infected individuals aged 25–44 years have an ~10–20 times increased incidence of
hospitalisation for influenza.[30] The relatively lower detection rates in our study likely reflect
the fact that HIV-infected individuals have a substantially elevated risk of other important
pathogens such as pneumococcus, Pneumocystis jirovecii and tuberculosis which contribute to
a greater proportion of SARI cases in the HIV-infected, rather than an absolute lower risk in
HIV-infected individuals. This has been described for respiratory viral infections in HIV-in-
fected children from South Africa.[31]
The overall case-fatality ratio was 7%, similar to other studies from Africa and the US.[3, 15,
18, 32, 33] Increasing age was a risk factor for death, similar to that observed in developed
country settings.[34] However, the median age at death was 42 years (36 years in HIV-infected
and 62 years in HIV-uninfected), lower than the median age at death in more developed set-
tings where death is more common in elderly individuals. HIV-infected individuals were 1.5
times more likely to die than HIV-uninfected individuals in contrast to other studies which
have found a similar mortality in HIV-infected and -uninfected individuals.[32, 35, 36] Earlier
studies included smaller numbers of cases and may have been underpowered to detect the rela-
tively modest increased relative risk of death. In addition, in other studies, HIV-uninfected in-
dividuals may have had a higher proportion of elderly or persons with underlying illness than
in our study. Receiving tuberculosis treatment on admission was also a risk factor for death. A
study in South African gold miners found that underlying lung damage from tuberculosis was
a risk factor for SARI mortality.[37] Patients who died had a shorter duration of hospitalisa-
tion, suggesting that death occurred early during admission. A longer duration of symptoms
prior to hospitalisation was also associated with increased mortality, thus delayed clinical pre-
sentation and subsequent delayed treatment initiation may have contributed to mortality in
some cases. Mechanical ventilation and supplementary oxygen therapy were independent pre-
dicators of mortality. It is likely that these factors are surrogates for disease severity. Unfortu-
nately, data on oxygen saturation were not available.
Approximately 40% of patients with available data reported receiving ART on admission.
Suggesting that even in the presence of ART, pneumonia remains a common clinical presenta-
tion in HIV-infected individuals. More than two thirds of patients with available data had se-
vere immunosuppression on CD4+ T cell count and a low CD4+ T cell count was associated
with increased mortality. Data on receipt of ART and CD4+T cell counts was unfortunately
available for less than half of all HIV-infected patients and no data on ART compliance or clin-
ical HIV stage was available potentially biasing results. In addition, data on socioeconomic sta-
tus of patients were not available.
Additional limitations of our study include that subjects were only tested systematically for
ten viruses and pneumococcus. Blood cultures were not performed systematically and we did
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not test for P. jirovecii or tuberculosis, important causes of pneumonia in HIV-infected individ-
uals.[36, 38] Our study may have underestimated mortality because severely ill cases may have
been less likely to consent to inclusion or may have died before or shortly after hospital admis-
sion prior to being consented, as has been previously suggested.[39] Our estimates of incidence
were only obtained from one surveillance hospital and assumed that all individuals in the com-
munity accessed care at CHBH hospital. In addition, we did not account for individuals who
did not seek care at all. Therefore our incidence and mortality estimates likely represent a mini-
mum estimate. Nevertheless, the estimates of relative risk by HIV status should be robust, un-
less patients had differential access to care by HIV-infection status. Missing information for
some of the predictors in our logistic regression model may have resulted in a loss of power
that may have potentially hindered our ability to assess significance for some of the predictors
assessed in our model and could have potentially introduced bias.
Efforts to promote earlier diagnosis of HIV infection and earlier ART initiation as well as
more widespread ART availability may reduce the substantial burden of disease in HIV-in-
fected individuals and improve outcomes in patients with SARI. Pneumococcus and influenza
were commonly detected aetiologies. This suggests that more widespread access to vaccination
against influenza and pneumococcus as well as indirect protection following the introduction
of pneumococcal conjugate vaccine in children in South Africa could also reduce the burden of
SARI.
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